Disability functional profile of patients with progressive multiple sclerosis and its association with disease-modifying therapy in a hospital in Northeastern Brazil
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Disability functional profile of patients with progressive multiple sclerosis and its association with disease-modifying therapy in a hospital in Northeastern Brazil ; volume:82 ; number:S 01 ; year:2024 ; 01
Konferenz: 25th BCTRIMS Annual Meeting; 2024-06-05; Tivoli Mofarrej São Paulo - SP
Arquivos de neuro-psiquiatria ; 82, Heft S 01 (2024), 01
- Contributor
-
de Alencar, Matheus Rolim Mendes
Nóbrega, Ivna Lacerda Pereira
Bessa, Igor
Lisboa, Paulo Sérgio
Rejane, Keyla
Barbosa, Rodrigo da Ponte
Silvestre, Lucas
D’Almeida, Patrícia Chagas Rocha
Martins, Gabriela
D’Almeida, José Artur Costa
Pitombeira, Milena Sales
- DOI
-
10.1055/s-0044-1789341
- URN
-
urn:nbn:de:101:1-2412121002477.468576696530
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- de Alencar, Matheus Rolim Mendes
- Nóbrega, Ivna Lacerda Pereira
- Bessa, Igor
- Lisboa, Paulo Sérgio
- Rejane, Keyla
- Barbosa, Rodrigo da Ponte
- Silvestre, Lucas
- D’Almeida, Patrícia Chagas Rocha
- Martins, Gabriela
- D’Almeida, José Artur Costa
- Pitombeira, Milena Sales
Other Objects (12)
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases